Review of a Commercially Available Hybrid closed-loop insulin-delivery System in the Treatment of Type 1 Diabetes

Abstract

Type 1 diabetes is an important medical condition causing significant burden and morbidity to those persons affected by it. Improvements in insulin products, insulin delivery and glucose monitoring technology have all contributed to reductions in long-term complications and hypoglycemia. This article reviews the Medtronic 670G device and summarizes the data supporting how this product reduces the burden and increases the safety of insulin dosing in Type 1 diabetes.

Keywords:

• artificial pancreas
• automated insulin delivery
• bionic pancreas
• closed-loop
• CSII
• diabetes
• insulin
• Medtronic 670G
• pump
• Type 1 DM

Company review

In addition to the peer-review process, with the authors’ consent, the manufacturer of the product discussed in this article was given the opportunity to review the manuscript for factual accuracy. Changes were made by the authors at their discretion and based on scientific or editorial merit only. The authors maintained full control over the manuscript, including content, wording and conclusion.

Financial & competing interests disclosure

Financial disclosure for T Bailey, MD: Research Support: Abbott, Ambra, Ascensia, BD, Boehringer Ingelheim, Calibra, Companion Medical, Dexcom, Elcelyx, Glooko, Glysens, Janssen, Lexicon, Lilly, Medtronic, Novo Nordisk, Sanofi, Senseonics, Versartis, Xeris Consulting Honoraria: Abbott, Astra Zeneca, Ascensia, BD, Calibra, Lilly, Medtronic, Novo Nordisk, Sanofi Speaking Honoraria: Abbott, Insulet, Medtronic, Lilly, Novo Nordisk, Sanofi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.